Allergy Therapeutics (AGY) — Tangible Net Worth Ratio
Allergy Therapeutics (AGY) has a Tangible Net Worth Ratio of 79.8% as of December 2025. This metric is calculated by deducting intangible assets (GBX860.00K) from net assets (GBX4.25 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore Allergy Therapeutics equity growth rate to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Allergy Therapeutics Tangible Net Worth Ratio (2003–2024)
This chart shows how Allergy Therapeutics's Tangible Net Worth Ratio has changed across 20 annual periods from 2003 to 2024. As of December 2025, the ratio stands at 79.8%, reflecting net assets of GBX4.25 Million with intangible assets of GBX860.00K GBX. For live market cap and overall valuation, see how much is Allergy Therapeutics worth.
Annual Tangible Net Worth Ratio for Allergy Therapeutics (2003–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Allergy Therapeutics from 2003 to 2024, covering 20 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore capital reinvestment ratio of Allergy Therapeutics to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Tangible NW Ratio | Net Assets (GBX) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 63.1% | GBX3.71 Million | GBX1.37 Million | GBX64.83 Million | ▲ +176.0 pp |
| 2023 | -113.0% | GBX2.07 Million | GBX4.40 Million | GBX66.77 Million | ▼ -199.6 pp |
| 2022 | 86.7% | GBX37.77 Million | GBX5.04 Million | GBX72.95 Million | ▼ -3.5 pp |
| 2021 | 90.2% | GBX48.53 Million | GBX4.75 Million | GBX88.09 Million | ▲ +1.0 pp |
| 2020 | 89.2% | GBX43.78 Million | GBX4.74 Million | GBX86.22 Million | ▼ -7.1 pp |
| 2019 | 96.3% | GBX37.56 Million | GBX1.41 Million | GBX68.50 Million | ▲ +2.9 pp |
| 2018 | 93.3% | GBX23.03 Million | GBX1.54 Million | GBX51.02 Million | ▲ +0.2 pp |
| 2017 | 93.1% | GBX29.96 Million | GBX2.07 Million | GBX57.18 Million | ▼ 0.0 pp |
| 2016 | 93.1% | GBX30.32 Million | GBX2.08 Million | GBX56.68 Million | ▼ -1.0 pp |
| 2015 | 94.1% | GBX34.47 Million | GBX2.02 Million | GBX50.70 Million | ▲ +2.7 pp |
| 2014 | 91.4% | GBX15.07 Million | GBX1.29 Million | GBX28.40 Million | ▲ +0.6 pp |
| 2013 | 90.8% | GBX14.67 Million | GBX1.35 Million | GBX28.96 Million | ▲ +5.2 pp |
| 2012 | 85.6% | GBX14.59 Million | GBX2.11 Million | GBX27.75 Million | ▲ +68.8 pp |
| 2011 | 16.7% | GBX2.14 Million | GBX1.78 Million | GBX30.62 Million | ▼ -61.1 pp |
| 2010 | 77.9% | GBX3.89 Million | GBX860.00K | GBX29.11 Million | ▼ -8.6 pp |
| 2007 | 86.5% | GBX8.60 Million | GBX1.16 Million | GBX23.99 Million | ▼ -19.1 pp |
| 2006 | 105.6% | GBX32.70 Million | GBX-1.82 Million | GBX37.88 Million | ▲ +10.3 pp |
| 2005 | 95.3% | GBX20.08 Million | GBX951.00K | GBX26.66 Million | ▲ +52.0 pp |
| 2004 | 43.2% | GBX7.08 Million | GBX4.02 Million | GBX11.23 Million | ▲ +23.1 pp |
| 2003 | 20.1% | GBX5.55 Million | GBX4.43 Million | GBX11.15 Million | — |